Skip to main content

Table 1 Baseline characteristics of patients and prevalence of circulating tumor cells (CTCs) according to clinicopathological variables

From: Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-A- trial

Variable All patients N = 1221 Patients without CTCs N = 970 Patients with CTCs N = 251 p-valuea
Age (years)     0.41b
 Median 53.0 53.0 54.0  
 Range 22 - 85 22 - 85 33 - 75  
Tumor stage     0.34c
 pT1 489 (40.0 %) 397 (40.9 %) 92 (36.7 %)  
 pT2 652 (53.4 %) 511 (52.7 %) 141 (56.2 %)  
 pT3 63 (5.2 %) 47 (4.8 %) 16 (6.4 %)  
 pT4 17 (1.4 %) 15 (1.5 %) 2 (0.8 %)  
Nodal stage     0.23c
 pN0 422 (34.6 %) 341 (35.2 %) 81 (32.3 %)  
 pN1 561 (45.9 %) 446 (46.0 %) 115 (45.8 %)  
 pN2 165 (13.5 %) 126 (13.0 %) 39 (15.5 %)  
 pN3 70 (5.7 %) 54 (5.6 %) 16 (6.4 %)  
 unknown 3 (0.2 %) 3 (0.3 %) 0 (0.0 %)  
Histological grading     0.30c
 G1 59 (4.8 %) 43 (4.4 %) 16 (6.4 %)  
 G2 604 (49.5 %) 479 (49.4 %) 125 (49.8 %)  
 G3 557 (45.6 %) 447 (46.1 %) 110 (43.8 %)  
 unknown 1 (0.1 %) 1 (0.1 %) 0 (0.0 %)  
Histological type     0.26d
 ductal 1019 (83.5 %) 812 (83.7 %) 207 (82.5 %)  
 lobular 122 (10.0 %) 91 (9.4 %) 31 (12.4 %)  
 other 80 (6.6 %) 67 (6.9 %) 13 (5.2 %)  
Hormone receptor status     0.73d
 negative 368 (30.1 %) 290 (29.9 %) 78 (31.1 %)  
 positive 851 (69.7 %) 678 (69.9 %) 173 (68.9 %)  
 unknown 2 (0.2 %) 2 (0.2 %) 0 (0.0 %)  
HER2 status     0.88d
 negative 906 (74.2 %) 720 (74.2 %) 186 (74.1 %)  
 positive 296 (24.2 %) 234 (24.1 %) 62 (24.7 %)  
 unknown 19 (1.6 %) 16 (1.6 %) 3 (1.2 %)  
Menopausal status     0.88d
 premenopausal 521 (42.7 %) 415 (42.8 %) 106 (42.2 %)  
 postmenopausal 700 (57.3 %) 555 (57.2 %) 145 (57.8 %)  
Type of surgery     0.27d
 breast conserving 876 (71.7 %) 703 (72.5 %) 173 (68.9 %)  
 mastectomy 345 (28.3 %) 267 (27.5 %) 78 (31.1 %)  
Radiotherapy     1.00d
 no 175 (14.3 %) 139 (14.3 %) 36 (14.3 %)  
 yes 1045 (85.6 %) 830 (85.6 %) 215 (85.7 %)  
 unknown 1 (0.1 %) 1 (0.1 %) 0 (0.0 %)  
Endocrine therapy     0.81d
 no 333 (27.3 %) 266 (27.4 %) 67 (26.7 %)  
 yes 887 (72.6 %) 703 (72.5 %) 184 (73.3 %)  
 unknown 1 (0.1 %) 1 (0.1 %) 0 (0.0 %)  
HER2-targeted therapy     0.54d
 no 965 (79.0 %) 770 (79.4 %) 195 (77.7 %)  
 yes 255 (20.9 %) 199 (20.5 %) 56 (22.3 %)  
 unknown 1 (0.1 %) 1 (0.1 %) 0 (0.0 %)  
  1. aAll tests without unknowns
  2. bMann–Whitney U test
  3. cCochran–Armitage test for trend
  4. dChi-square test